ClinicalTrials.gg
RecruitingNCT06896903CRT-NITROUpdated May 5, 2026

Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing

An interventional study of Coronary reactivity testing with and without nitrates in ANOCA - Angina With Non-obstructive Coronary Arteries and INOCA (Ischemia With Non Obstructive Coronary Artery Disease), sponsored by Baylor Research Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Baylor Research Institute · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Planned enrollment
509th of 745
50 · median 107
Started
2025
with 31 others
No phase
352 of 1,104
41 open now
Primary completion
2027-05
later than 56 of 141 live
Registered
1,062nd of 1,104
by date

Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 509th largest by planned enrollment of the 745 interventional ones that give a count, is one of 32 that started in 2025, is one of 352 with no phase, reaches primary completion later than 56 of the 141 other live ones, and was the 1,062nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,104 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

This single-arm, multi-center, prospective study will assess the coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and determinants thereof (transit time, Pa, Pd) in patients before and after intracoronary nitroglycerine.

Read the detailed description

This will be a single arm, multi-center, prospective interventional study. We will approach, consent, and enroll patients referred to the cardiac catheterization laboratory for coronary angiography for the indication of angina without obstructive coronary artery disease (CAD; lesions \<50%, fractional flow reserve (FFR) >0.80, or non-hyperemic pressure index (RFR) \<0.89). Patients will undergo invasive assessment with CRT first without IC nitrates followed by a dose of 200-500 mcg of intracoronary nitrates and repeat CRT.

Approximately 50 patients undergoing coronary angiography for evaluation of ANOCA or INOCA will be consented for this study.

The primary outcome will be comparing the variables assessed by CRT with the primary outcome being CFR before and after nitroglycerin administration.

The secondary outcomes will be IMR, Pd, Pa, RRR, and transit times before and after nitrates.

These variables will be compared to one another using paired t-tests and generalized estimating equations.

03

Conditions studied

  • ANOCA - Angina With Non-obstructive Coronary Arteries
  • INOCA (Ischemia With Non Obstructive Coronary Artery Disease)

Keywords

  • Coronary Reactivity Testing
  • Intracoronary Nitroglycerine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 or older
  2. Patient being evaluated for ANOCA or INOCA
  3. Clinical suspicion for angina
  4. Patient should be able to comply with the protocol.
  5. Provide written before study participation.

Exclusion criteria

Exclusion Criteria:

  1. Existing coronary artery disease
  2. Previous percutaneous interventions within the coronaries
  3. Current use (within 48 hours) of long-acting nitrate therapies
  4. Current use (within 48 hours) of PDE-5 inhibitors (sildenafil, tadalafil)
  5. Any other condition or co-morbidity which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study.
  6. Children below 18 years, prisoners, pregnant people and patients who are unable to provide consent are excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Coronary Reactivity Testing with and without intracoronary nitroglycerine

    CRT will be performed in the left anterior descending and right coronary arteries. The following measures will be obtained in each of the coronaries first without intracoronary nitrates followed by a dose of 200-500 mcg of intracoronary nitrates and repeat measurements: * Coronary flow reserve (CFR) (normal \> 2.0) * Index of microvascular resistance (IMR) (normal \<25) * Resting ratio of distal coronary pressure to aortic pressure (Pd/Pa) (normal \< 0.91) * Resting and hyperemic (using intravenous adenosine) transit time (Tm) * Resting full-cycle ratio (RFR) * Hyperemic (using intravenous adenosine) fractional flow reserve (FFR) * Resistive reserve ratio (RRR)

    Diagnostic Test: Coronary reactivity testing with and without nitrates

Interventions

  • Diagnostic testCoronary reactivity testing with and without nitrates

    CRT will be performed in the left and right coronary arteries. Measurements will be obtained in each of the coronaries first without intracoronary nitrates followed by a dose of 200-500 mcg of intracoronary nitrates and repeat measurements.

06

What researchers measure

Primary outcomes

  1. Assessment of CFR by CRT before and after nitrates

    The primary outcome will be comparing the variables assessed by CRT with the primary outcome being CFR before and after nitroglycerin administration.

    Time frame: Intra op

Secondary outcomes

  1. IMR, HMR, Pd/Pa, RRR, RFR, and transit times before and after nitrates.

    The secondary outcomes will be IMR, Pd, Pa, RRR, and transit times before and after nitrates.

    Time frame: Intra op

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Smilowitz NR, Prasad M, Widmer RJ, Toleva O, Quesada O, Sutton NR, Lerman A, Reynolds HR, Kesarwani M, Savage MP, Sweeny JM, Janaszek KB, Barseghian El-Farra A, Holoshitz N, Park K, Albadri A, Blair JA, Jeremias A, Kearney KE, Kobayashi Y, Miner SES, Samuels BA, Shah SM, Taqueti VR, Wei J, Fearon WF, Moses JW, Henry TD, Tremmel JA; Microvascular Network (MVN). Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Sep 19;82(12):1264-1279. doi: 10.1016/j.jacc.2023.06.044. PubMed 37704316 ↗
  • Samuels BA, Shah SM, Widmer RJ, Kobayashi Y, Miner SES, Taqueti VR, Jeremias A, Albadri A, Blair JA, Kearney KE, Wei J, Park K, Barseghian El-Farra A, Holoshitz N, Janaszek KB, Kesarwani M, Lerman A, Prasad M, Quesada O, Reynolds HR, Savage MP, Smilowitz NR, Sutton NR, Sweeny JM, Toleva O, Henry TD, Moses JW, Fearon WF, Tremmel JA; Microvascular Network (MVN). Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Sep 19;82(12):1245-1263. doi: 10.1016/j.jacc.2023.06.043. PubMed 37704315 ↗
  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. No abstract available. PubMed 31504439 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 26, 2025
StartActual
May 21, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 1, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06896903
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
May 21, 2025
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
May 5, 2026

Study contacts

Bonnie Ostergren
Contact
Bonnie.Ostergren@bswhealth.org
469-814-4181

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion